A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
Explore this paper's citation graph
- Type
- article
- Published
- 2013-07-01
- Cited by
- 137
- References
- 18
- Access
- Open access
- OpenAlex
- https://openalex.org/W23585522
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:15124875
Keywords
Ultimate tensile strength, Lime, Compressive strength, Materials science, Geotechnical engineering
References
- International scoring system for evaluating prognosis in myelodysplastic syndromes.
- The effect of chemotherapy on acute leukemia in the human.
- Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.
- Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
- A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias.
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- Analysis of survival by tumor response.
- Report of an international working group to standardize response criteria for myelodysplastic syndromes.
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.
- Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.
- Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60).
- A new look at the statistical model identification
- DNA methylation and gene expression
- Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables.
- Management of patients with higher risk myelodysplastic syndromes.
- Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes.
- Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission
Cited by
- The outcome of patients with high‐risk MDS achieving stable disease after treatment with 5‐azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group
- Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real‐world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia
- New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
- Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the ‘real life’ setting: A single center observational study
- Azacitidine in untreated acute myeloid leukemia: A report on 149 patients
- RETRACTED ARTICLE: 5-Azacitidine for treating acute myelogenous leukemia
- Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response
- Pharmacokinetics of different formulations of oral azacitidine (CC‐486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies
- Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy
- Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents
- Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management
- Epigenetics of myelodysplastic syndromes
- Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.
- DNA Methylation and Cancer Diagnosis
- Transplants in myelodysplastic syndromes.
- Current therapy of myelodysplastic syndromes
- Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.
- Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine
- Has introduction of azacytidine in everyday clinical practice improved survival in late-stage Myelodysplastic syndrome? A single center experience.
Related papers
- A Study on Tensile Strength of Compacted Fine-Grained Soils
- STATISTICAL RELATIONS BETWEEN COMPRESSIVE AND TENSILE STRENGTHS OF SOIL- CEMENT
- Evaluation of Ratio Between Splitting Tensile Strength and Compressive Strength for Concretes up to 120 MPa and its Application in Strength Criterion
- INTERDEPENDENCE OF CONCRETE STRENGTH PARAMETERS
- EVALUATION OF FACTORS AFFECTING THE TENSILE PROPERTIES OF LIME-TREATED MATERIALS
- SOIL-CEMENT MIXES - A CRITICAL EVALUATION
- Evaluating the co-relationship between concrete flexural tensile strength and compressive strength
- SPLIT CYLINDER TEST APPLIED TO BITUMINOUS MIXTURES AT LOW TEMPERATURES
- A STANDARD TEST PROCEDURE FOR TENSILE STRENGTH OF CONCRETE